Navigation Links
Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
Date:6/9/2008

SAN FRANCISCO, June 9 /PRNewswire/ -- Two long-term, large-scale and independent studies evaluating cardiovascular (CV) outcomes in people with type 2 diabetes enrolled more than 9,300 patients taking AVANDIA(R) (rosiglitazone maleate) and provide more than 20,000 patient years of additional experience with AVANDIA. The Veterans Affairs Diabetes Trial (VADT), through two separate analyses, concluded that based on results from VADT, there is no evidence to suggest that use of AVANDIA increases the risk for CV mortality and morbidity in patients with type 2 diabetes. A second trial, The Action to Control Cardiovascular Risk in Diabetes (ACCORD), found that AVANDIA was not associated with any increased risk of death. These findings display a safety profile consistent with results from other long-term studies with AVANDIA. These studies were presented during the 68th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA.

"The findings on AVANDIA should be reassuring to physicians who prescribe AVANDIA and patients who use AVANDIA for their type 2 diabetes," added R. Paul Aftring, MD, PhD, AVANDIA Clinical Lead at GlaxoSmithKline. "The safety findings on AVANDIA from these two trials add substantial patient experience to the large body of existing evidence on the safety profile of the medication."

Findings from VADT

VADT evaluated whether intense blood sugar control in patients with type 2 diabetes would reduce major CV events. The study continued for 7.5 years. In total, 1,704 patients enrolled in VADT took AVANDIA.

The primary result of VADT did not show that intensive blood sugar control (HbA1c levels below 7%) had a statistically significant effect on reducing major CV events associated with diabetes. However, there was a favorable trend in reducing all CV events, except CV death and inoperable heart disease, among the patients in the intensive arm. There were significantly fewer CV events in the trial
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
2. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
5. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
9. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
10. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
11. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... ), the leading source of health information, ... on the new National Action Plan ... interview, President Obama emphasized the urgency and ... impact on national and global health.    ...
(Date:3/26/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... therapies for cardiovascular disease and overall health, announced that ... of the Corporation (the "Common Shares"). The Common Shares ... 5 th , 2014 to March 4 th , ... on or before April 1, 2015. Interest on the ...
(Date:3/26/2015)... "Whether it,s our family, our friends, all ... In a single sentence, Dr. Anthony Coyle , ... Centers for Therapeutic Innovation (CTI), sums up ... America,s biopharmaceutical companies. CTI,s unique model ... foundations and the National Institutes of Health (NIH) to ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... , BOZEMAN, Mont., Sept 8 ... its third human clinical trial of its norovirus vaccine. ... with LigoCyte,s investigational, nasally-delivered, dry powder vaccine in healthy adults. ... of norovirus infection by including a live virus challenge of ...
... , MORGANTON, W.Va., Sept. 4 People with chronic ... and depression than people treated conventionally for back pain, a West ... , , The three-year, $400,000 study, published in ... pain and improved function in the group that did yoga postures ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 2LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge 3Yoga Benefits Back-Pain Patients 2
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... March 29, 2015 North American Seminars ... PT Online Continuing Education Courses . , ... of CME - TPTA, approval # 56399TX      , ... of the shoulder complex - 10.5 hours - Texas ... , Examination and Treatment of the SI Joint - ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... York, New York (PRWEB) March 28, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. Bard, ... litigation underway in U.S. District Court, Southern District ... S. Grand, is serving on the Plaintiffs’ Steering ... 24th, the Court has granted certain defendants named ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4
... pet food continues to takes it toll in the US. ... //was placed under quarantine following detection of the industrial chemical ... testing was under way to determine if the chemical was ... 3, according to the California Department of Food and Agriculture ...
... Network is very near to achieving one of today’s Science ... health conditions.// ,As well as from the UGR, ... and Reus also took part in this study, concluding that ... small amounts by human beings and present in many types ...
... commonest medical disorder in pregnancy, adversely affecting maternal ... at control and treatment of anemia during pregnancy, ... the majority of women present late. ... have consequences that extend over generations. Girls born ...
... Dev has launched a seven-day camp in this Taj Mahal ... other licentious activities.// ,Ram Dev, who enjoys wide following ... education being given to the young. ,'A balanced ... he said. ,Later speaking to journalists, Ram Dev ...
... may have the most significant impact in reducing ... Americans and Caucasians, according to a new study. ... CANCER, a peer-reviewed journal of the American Cancer ... demonstrated that when socioeconomic factors and treatment utilization ...
... concerned citizens. Delhi, burning under the scorching summer sun, heralded ... issues that are pricking our fragile ecosystem. ,'We ... of Toxics Link, an environmental NGO. 'The issue of stopping ... needs to be addressed immediately and a day such as ...
Cached Medicine News:Health News:Pigs Quarantined in US Farm Following Melamine Contamination 2Health News:High Melatonin can Help Delay Ageing 2Health News:Social Factors Not Genetics Drive Racial Disparities in Colorectal Cancer Survival 2Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
... up to 20 tilting ... in the vertical, horizontal ... the option to offset ... transillumination., ,Filters include Cobalt ...
An easy to use uncomplicated ophthalmoscope....
With a high lens and filter range this ophthalmoscope is ideal for the Primary Care Specialist...
Medicine Products: